*Department of Surgery, University Medical Center Utrecht, Utrecht, The Netherlands †Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
Ann Surg. 2017 Nov;266(5):863-869. doi: 10.1097/SLA.0000000000002389.
To evaluate the impact of lymph node yield (LNY) on survival in patients treated with neoadjuvant chemoradiotherapy (nCRT) followed by esophagectomy for cancer.
The value of an extended lymphadenectomy after nCRT for esophageal cancer is debated. Recent reports demonstrate no association between LNY and survival. This association has not yet been evaluated in larger cohorts.
All patients who underwent nCRT followed by esophagectomy between 2005 and 2014 were identified from the Netherlands Cancer Registry. The association between LNY and overall survival was analyzed using multivariable Cox regression analyses, adjusting for diagnosis year, referral, hospital volume, age, sex, malignancy history, tumor location, histology, cTN-stage, surgical approach, radicality, and ypTN-stage. Analyses were performed with LNY as categorized predictor (<15 vs ≥15 nodes) and continuous predictor (per 10 additionally nodes).
A total of 2698 patients were included with a median overall survival of 34 months (range 4-143). A higher LNY was significantly associated with improved overall survival, both as categorized predictor (hazard ratio 0.77, 95% confidence interval 0.68-0.86) and as continuous predictor (hazard ratio 0.84, 95% confidence interval 0.78-0.90). Furthermore, a higher LNY was associated with favorable hazard ratios across subgroups, including both squamous cell carcinoma and adenocarcinoma, both cN0 and cN+, both transthoracic and transhiatal approaches, and both ypN0 and ypN+.
This large population-based cohort study demonstrates an association between LNY and overall survival, indicating a therapeutic value of extended lymphadenectomy during esophagectomy. Therefore, an extended lymphadenectomy should be the standard of care after nCRT.
评估新辅助放化疗(nCRT)后行食管癌切除术的患者中淋巴结检出量(LNY)对生存的影响。
nCRT 后行扩大淋巴结清扫术治疗食管癌的价值存在争议。最近的报告表明,LNY 与生存无关联。但这一关联尚未在更大的队列中进行评估。
从荷兰癌症登记处确定了 2005 年至 2014 年间接受 nCRT 后行食管癌切除术的所有患者。使用多变量 Cox 回归分析,调整诊断年份、转诊、医院容量、年龄、性别、恶性肿瘤病史、肿瘤位置、组织学、cTN 分期、手术方式、根治性和 ypTN 分期后,分析 LNY 与总生存之间的关系。分析时,LNY 分别作为分类预测因子(<15 个 vs ≥15 个淋巴结)和连续预测因子(每增加 10 个额外淋巴结)。
共纳入 2698 例患者,中位总生存期为 34 个月(范围 4-143)。较高的 LNY 与总生存显著相关,既是分类预测因子(风险比 0.77,95%置信区间 0.68-0.86),也是连续预测因子(风险比 0.84,95%置信区间 0.78-0.90)。此外,LNY 较高与亚组的有利风险比相关,包括鳞癌和腺癌、cN0 和 cN+、经胸和经食管裂孔入路、ypN0 和 ypN+。
这项大型基于人群的队列研究表明 LNY 与总生存之间存在关联,表明 nCRT 后行扩大淋巴结清扫术具有治疗价值。因此,nCRT 后应将扩大淋巴结清扫术作为标准治疗。